MedPath

Nilutamide

Generic Name
Nilutamide
Brand Names
Anandron, Nilandron
Drug Type
Small Molecule
Chemical Formula
C12H10F3N3O4
CAS Number
63612-50-0
Unique Ingredient Identifier
51G6I8B902

Overview

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Background

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Indication

用于已转移的前列腺癌,可与手术或化学去势合用。

Associated Conditions

  • Metastatic Prostate Cancer

FDA Approved Products

Nilandron
Manufacturer:Concordia Pharmaceuticals Inc.
Route:ORAL
Strength:150 mg in 1 1
Approved: 2022/07/08
NDC:59212-111
Nilutamide
Manufacturer:ANI Pharmaceuticals, Inc.
Route:ORAL
Strength:150 mg in 1 1
Approved: 2020/09/18
NDC:62559-173
Nilutamide
Manufacturer:Prasco Laboratories
Route:ORAL
Strength:150 mg in 1 1
Approved: 2019/11/22
NDC:66993-212

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath